A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00010612/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
提供机构：
Vivli
创建时间：
2024-10-10
